01....
|
|
|
- なごみ ありはら
- 9 years ago
- Views:
Transcription
1 , , , ,40010, ,246 2 Vol. 22 No
2 Vol. 22 No
3 4 Vol. 22 No P450CYP CYP CYP3A CYP CYP3A
4 5 Vol. 22 No pharmacokinetics pharmacodynamics 5-FU 7080 P450 P450 P450 P450 P P450 GOT P450 P450 CYP P450 CYP1A
5 Family Subfamily P450 CYP1 CYP1A CYP1A1 benzo[a]pyrene polycyclic aromatic hydrocarbons, cigarettes, omeprazole CYP1A2 13 caffeine, phenacetin, theophylline, taurine CYP2 CYP2A CYP2A6 CYP2A7 coumarin CYP2B CYP2B6 cyclophosphamide phenobarbital CYP2B7 CYP2C CYP2C8 tolbutamide rifampicin, phenobarbital CYP2C9 warfarin, NSAIDs, phenytoin mephenytoin, diazepam, 20 hexobarbital, R-mephobarbital, CYP2C19 omeprazole and other PPIs, proguanil, ethotoin CYP2D CYP2D6 2 metoprolol and other blockers, dextromethorphan, imipramine and other tricyclics, codeine, flecainide and other type IC antiarrhythmics, phenformin, sparteine, thioridazine, debrisoquine (total of ca. 30 drugs) CYP2E CYP2E1 7 ethanol, chlorzoxazone ethanol, isoniazid CYP3 CYP3A CYP3A3/4 CYP3A5 30 nifedipine and other dihydropyridines, ciclosporin, tacrolimus, testosterone, erythromycin and other macrolides, lidocaine, triazolam, quinidine, carbamazepine, terfenadine testosterone rifampicin, phenytoin, carbamazepine CYP4 CYP4B CYP4B1 testosterone clofibrate furafylline, enoxacin and some new quinolones, methoxalen, cimetidine sulfaphenazole, cimetidine omeprazole, cimetidine quinidine, fluoxetine, paroxetine, perphenazine, haloperidol, cimetidine chlormethizole, diehtyldithiocarbamate ketoconazole, itraconazole gestodene, diltiazem, verapamil, erythromycin, naringenin CYP1A1CYP1A2 P450 P450 P450 P450 6 Vol. 22 No
6 7 Vol. 22 No P450 P Hayton ergotism 20 N- P450 P450 P450 P450CYP3A P4503A33A43A53A7 3A7 CYP3A4 CYP3AP450 P P450 CYP3A CYP3A CYP3A P450 P450 P450 P450 P450
7 P450 in vitrop450 P in vitrop450 P450 CYP3A CYP1A2 P450 P450mixed function oxidase P450 P450 P450 P450 CYP3ACYP2D6 P450 CYP3A P450 P450 P450 P450in vitro P450 8 Vol. 22 No
8 1998 Rowland M and Tozer TN : Clinical Pharmacokientics : Concept and Application, 3rd ed., Williams & Wilkins, Baltimore, 1995 Vol. 22 No
9 R DDSdrug delivery system DDS DDS DDS Vol. 22 No
10 12 Vol. 22 No
11 O/W W/O O/W W/O O/W O/W Vol. 22 No
12 O/W 14 Vol. 22 No
13 15 Vol. 22 No ODT ODT ODT ODT ODT ODT ODT ODT ODT ODT ODTFU ODT McKenzie
14 VI strongest ,869 1,600 1, ,660 1,660 1,700 -DP very strong , , strong V medium A weak Rook McKenzie and AtkinsonStoughton RB Vol. 22 No
15 MIC Dermatofile Vol. 22 No
16 18 Vol. 22 No FAPG 1/2
17 19 Vol. 22 No PL O/W W/O suppl
18 ddddddddddddddddddddddddddddddddddddddddddddd ddddddddddddddddddddddddddddddddddddddddddddd Vol. 22 No
19 T TB 22 Vol. 22 No
20 Vol. 22 No
21 T T CD86T CD28CD86CD28 24 Vol. 22 No
22 T T deletion suppression anergy Vol. 22 No
23 T 26 Vol. 22 No
24 MHC MHC MHC HLA-GMHC Vol. 22 No
25 Vol. 22 No
26 29 Vol. 22 No
27 30 TTS1999 TTS10TTS20TTS3024 TTS30 TTS20TTS1010 TTS Vol. 22 No
28 TTS TTS TTS ,000,000US$198Mio US$1998 Vol. 22 No
29 32 Vol. 22 No
30 karuophullon carophilum Vol. 22 No
31 Vasco da Gama Amboina 1770 Mauritius1788 Penang Zanzibar Madagascar Vol. 22 No
32 Clou Clove Eugenia Syzygium syzygos aromaticum CloveClou de Girofle GewürznelkenbaumGarofani Syzygium aromaticum Merrill et L. M. Perry 12m cm cm 1.3cm 2.5cm 1.2cm S. buxifolium Hook et Arn. S. cleyerifolium Makino Malabar plum, rose apple jambosier, pomme rose Jambos, Rosenaptel S.jambos (L.)Alston 12m 15 20cm 2.5cm Rhum de Pommerose Jambosin Iarge-fruited rose, Malay apple S. malaccense(l.)merrill et L. M. Perry 14m 20 30cm1014cm cm cm 36 Vol. 22 No
33 Black plum, jambolan, S. cuminii (L.) Skeels 13m 2.3cm 1319 rosewater apple jambo ayer wässeriger S. aqueum Alston 10m 1530cm cm 1619 Eugenol 7895 Acetly-eugenol -- Caryophyllene Vanillin Tannin 10Oleanolic acid g Vol. 22 No
34 Vol. 22 No
35 NASAICAO 40 Vol. 22 No
36 41 Vol. 22 No CRMCRM CRM B P E
37 42 Vol. 22 No CRM PDSplan do see CRM
38 43 Vol. 22 No CRM CRM CRM CRM
39 stop and look 44 Vol. 22 No
40 45 Vol. 22 No stop and look one thousand one thousasnd KLM
41 C3 KLM ATC KLM 400m we are at take off KLM CRM Vol. 22 No
42 47 Vol. 22 No
43 OTC Vol. 22 No
44 50 Vol. 22 No ACE
45 51 Vol. 22 No
46 52 Vol. 22 No F 33
47 53 Vol. 22 No PR
48 ADLQOL 54 Vol. 22 No
49 55 Vol. 22 No
50 56 Vol. 22 No
51 20 Vol. 22 No
52 59 Vol. 22 No (1)(2) (1) (2)
53 / / COPD/ 3F JR FAX FAX FAX FAX FAX FAX / // / SCS WHO FAX [email protected] WHO Vol. 22 No
54 Vol. 22 No
55 Vol. 22 No
56 65 Vol. 22 No (1) (2) (1) (2) 2,000 2,
57 66 Vol. 22 No No FAPA , ISDN
58 67 Vol. 22 No ,
59 68 Vol. 22 No , JR10 JR10 JR P450
60 TEL
61 28 21
62 14
63
医薬品開発における SimCYP の 利用 第一三共株式会社 薬物動態研究所 井上晋一
医薬品開発における薬物間相互 作用予測の意義 第一三共株式会社 薬物動態研究所 井上晋一 医薬品開発における SimCYP の 利用 第一三共株式会社 薬物動態研究所 井上晋一 医薬品開発における薬物間相互作用予測 / シミュレーションの意義 薬物相互作用 (DDI) のない安全な医薬品を開発する DDI の程度を前臨床段階で見積もる 2 医薬品開発における薬物間相互作用予測 / シミュレーションの意義
Vol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11
Vol.170 2004.9.9 9 17 9 17 1000 8 10 9 17 14:00 17:00 30 28 Vol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11 9.17 10 15 38 51 53 55 6 2
12 12 343 936 PR 2 3 11 11 11 12 12 12 14 15 15 15 16 20 20 21 23 23 23 24 25 10 4 26 26 27 27 27 28 2000 28 28 28 29 30 30 30 31 31 32 32 34 34 35 35 36 36 36 36 37 37 37 37 40 41 5 6 NHK 14 4 7 () NHK
870727_ガイドブック2016_vol1.indd
VOL.1 VOL.2 VOL.3 2016 I N D E X C h e c k! 3 C h e c k! 4 5 1 2 3 6 4 C h e c k! 5 7 8 9 10 11 12 Q Q Q A A A Q A C h e c k! 13 14 1,531,513 72,364 3,737,465 1,110,000 3,337,105 1,119,421 C h e c k! 774,000
1 1 (1) 1 1 1 (2) 1 (3) 3 3 4 4 2 6 (1) 6 (2) 6 6 6 7 3 7 (1) 7 7 9 10 10 11 (2) 12 12 14 16 (3) 17 17 18 (4) 18 18 18
1 1 (1) 1 1 1 (2) 1 (3) 3 3 4 4 2 6 (1) 6 (2) 6 6 6 7 3 7 (1) 7 7 9 10 10 11 (2) 12 12 14 16 (3) 17 17 18 (4) 18 18 18 ( ) 20 10 26 39 1 2 ( ) 3 338 4 5 6 22 10 7 50 60 8 600 400 600 400 9 10 454 11 45
新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
1 2441 2711 7 126 3 1 20 244127 11 18 9 B 10,000 10,000 1 1 40 60,000 28,000 98,000 1 20 100,000 22,000 132,000 7 2 1,014,000 7 2 924,000 1 2 317
1 2441 2711 7 126 3 1 20 244127 11 18 9 B 10,000 10,000 1 1 40 60,000 28,000 98,000 1 20 100,000 22,000 132,000 7 2 1,014,000 7 2 924,000 1 2 317 40 60 2 3 4 4 7 9 12 2 3 3 4 1 414 26 1. 2. 3. 4. 5. 6.
Wa Da m 12-2-
22 2010 1 10 22 2010 1 10 10 45 55 41 1908 17 2005 22 2010 55 20 2008 / -1- Wa Da 22 2010 55 1862 929m 12-2- -3- -4- -5- -6-22 2010 1 10 1000 1000 10 1000 10 9 11cm 10 45 12 45 9 11cm internet -7- 55 55
02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3) 16 3 17 182
![02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3) 16 3 17 182](/thumbs/40/20556211.jpg "02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3) 16 3 17 182")
6-3. 1. 01. [ 2000 (2003/3),p.161] 02. 1 2 3 1 2 [ 2000 (2003/3),p.160] 03. 12 1 13 15 3 [ 2000 (2003/3),p.207] 04. C C 27 C (1) (2) 3 00 3 C 181 02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3)
橡サプリメント.PDF
Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004
IF_SUPRECUR_N29
! @ # $ % ^ & * ( ) _ + )# ! a s d a s d f g h a s d @ a s d a s # a s d f g h j $ a s d f g h a s d % a s a a s a s a s d f g ^ a s a s a s & a s d f a s d f g h a s d f g a s d f g a s d a s d * s
サプリメント4.PDF
Vol.13,No,2004 106 Oct.200Vol.13 No. ACE 1000 10mmHg ACE ACE ACE Vol.13,No.4,2004 107 L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA Vol.13,No,2004 108 n-6
レジャー産業と顧客満足の課題
1 1983 1983 2 3700 4800 5500 3300 15 3 100 1000 JR 4 14 2000 55% 72% 1878 2000 5 ( ) 22 1,040 5 946 42 15 25 30 30 4 14 39 1 24 8 6 390 33 800 34 34 3 35 () 37 40 1 50 40 46 47 2 55 4.43 4 16.98 40 55
１ 発病のとき
1 3 2002 11 26 27 5 2003 1 15 16 9 2003 4 16 17 10 2003 6 25 26 12 2003 9 17 13 2003 11 12 13 16 2004 4 21 22 17 2004 5 19 20 18 2004 6 15 17 2004 6 17 20 2004 7 14 15 21 2004 8 18 19 2004 8 19 22 2004
1 2420128 1 1 6 3 2 198808 189/1 1988081891 3 4 5 JISJIS X 0208 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 1... 1... 2... 3... 3... 8... 8... 8... 9 2... 9... 9... 10... 11... 13...
JOMF-ｷｯｽﾞﾈｯﾄQ&Aﾌﾞｯｸ
Q&A Q&A A B Hib Hib DPT A MMR A MMR M measles M mumps R rubella MMR MMR MMR MMR MMR A BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG A A WHO A A B C D E A B A B B s DPT B B B A Vi A A O A
紀要No.9_006王_CS.indd
1 2 3 4 5 87 9 2009 1937.1 6 1937.1 2 1937.3 1937.9 73 1941.6 77 1941.10 27 1943.9 1943.10 1944.12 1946.12 1947.1 5 1948.4 L 1949.9 10 1950.10 1953.1 1953.12 1956.5.16 1956.6 1966.9 30 1966.10 1967.4 1967.9
untitled
CA 04 1,360 100.8 0.1 83 34,176 7.61 0.40 51,532 1.3 322,736 5.9 05 1,369 100.0 0.8 80 57,269 7.86 0.43 55,001 6.7 311,107 3.6 06 1,370 99.8 0.2 83 48,250 7.73 0.46 56,369 2.5 319,129 2.6 06/ 1-3 99.4
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
28.3% 0.2% n=418 34.8% 21.6% 15.1% 0.2% n=418 55.2% 44.6% 0.2% 42.9% n=418 1.4% 4.1% 5.0% 8.6% 25.9% 11.8% 3.6% 0.2% 35.0% 1.9% 14.6% n=418 11.5% 16.5% 5.0% 11.5% n=418 23.0% 0.2% 8.4% 3.1% 9.6% 55.7%
6 1873 6 6 6 2
140 2012 12 12 140 140 140 140 140 1 6 1873 6 6 6 2 3 4 6 6 19 10 39 5 140 7 262 24 6 50 140 7 13 =1880 8 40 9 108 31 7 1904 20 140 30 10 39 =1906 3 =1914 11 6 12 20 1945.3.10 16 1941 71 13 B29 10 14 14
untitled
Vol.27 1 Vol.27 2 Vol.27 3 Vol.27 4 Vol.27 5 Vol.27 6 Vol.27 7 Vol.27 8 Vol.27 9 Vol.27 10 11 Vol.27 Vol.27 12 Vol.27 13 Vol.27 14 Vol.27 15 Vol.27 16 Vol.27 17 Vol.27 2007 10 29 18 http://www.nira.or.jp/index.html
みさき_1
2 3 4 5 6 7 1F 2F 8 9 10 11 17 18 19 20 21 22 23 24 31 25 26 27 28 29 30 8 1 2 3 4 5 6 7 6 8 7 16 7 8 9 10 11 12 14 15 13 17 23 Vol.41 8 6 20 11 7 15 7 23 7 7 7 16 23 23 8 13 18:00 22:00 722
H21_report
vol.4 1 2 6 10 14 18 20 22 24 25 1 2 2172 73 3 21925 926 21125 126 4 5 6 21629 630 7 21107 108 21127 128 8 9 10 21616 617 11 211026 1027 211213 1214 12 13 14 21713 714 15 2194 95 211031 111 16 17 18 19
2009-9-2.indd
Q No.1441 Q No.1442 Vol.33 NO.9 (2009) 30 (614) Q No.1443 Vol.33 NO.9 (2009) 31 (615) Q No.1444 Vol.33 NO.9 (2009) 32 (616) Vol.33 NO.9 (2009) 33 (617) Vol.33 NO.9 (2009) 34 (618) Q No.1445 Vol.33 NO.9
09030549_001.図書館31-1
vol.31 NO.1 2 3 5 6 10 12 8 1947-1954- 1950-1838-1904 1952-1996 1 913-1954 1981-1958- 1 902-1992 1972-1946- 1 940- 1 2 3 3 5 6 6 8 8 12 8 8 1 2 2 http://library.hokkai-s-u.ac.jp/cgi-bin/tosyokan/index.cgi
